<DOC>
	<DOCNO>NCT02561806</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy study drug ixekizumab compare ustekinumab participant moderate-to-severe-plaque psoriasis .</brief_summary>
	<brief_title>A Study Ixekizumab ( LY2439821 ) Participants With Moderate-to-Severe Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Chronic plaque psoriasis least 6 month baseline Failure , contraindication , intolerability least 1 systemic therapy ( include cyclosporine , methotrexate , phototherapy ) PASI score least 10 screen baseline Participant must agree use reliable method birth control study ; woman must continue use birth control least 15 week stop treatment Predominant pattern pustular , erythrodermic , and/or guttate form psoriasis History druginduced psoriasis Can avoid excessive sun exposure use tan booth least 4 week baseline study Have receive systemic nonbiologic psoriasis therapy phototherapy within 4 week baseline , topical psoriasis treatment within 2 week baseline Concurrent recent use biologic agent within follow washout period : etanercept &lt; 28 day ; infliximab , adalimumab , alefacept &lt; 60 day ; golimumab &lt; 90 day ; rituximab &lt; 12 month ; biologic agent &lt; 5 halflives prior baseline Have prior use ustekinumab , condition contraindication ustekinumab would preclude participant participate protocol Have previously complete withdrawn study , participate study ixekizumab , participate study investigate interleukin ( IL ) 17 IL12/23 antagonist , receive treatment IL17 IL12/23 antagonist Have live vaccination within 12 week baseline , intend live vaccination course study within 15 week complete treatment study Have vaccination Bacillus CalmetteGu√©rin ( BCG ) within 12 month baseline intend vaccination BCG course study within 12 month complete treatment study Have know allergy hypersensitivity latex Have major surgery within 8 week baseline require study Have active history malignant disease within 5 year prior baseline Significant uncontrolled disorder Ongoing infection serious infection within 12 week baseline ; serious bone joint infection within 24 week baseline Are woman lactate breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>